Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 MeetingGlobeNewsWire • 03/16/23
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101GlobeNewsWire • 11/03/22
Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder ValueSeeking Alpha • 10/19/22
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)GlobeNewsWire • 10/19/22
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)GlobeNewsWire • 10/04/22
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine SummitGlobeNewsWire • 09/22/22
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines ConferenceGlobeNewsWire • 09/13/22
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price RuleGlobeNewsWire • 05/19/22
Abeona Therapeutics (ABEO) CEO, Vishwas Seshadri on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human PrimatesGlobeNewsWire • 05/04/22
Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingGlobeNewsWire • 04/29/22
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred StockGlobeNewsWire • 04/29/22